Researchers at the University of Bonn discover a new signaling pathway to combat excess body weight
The number of overweight persons is greatly increasing worldwide – and as a result is the risk of suffering a heart attack, stroke, diabetes or Alzheimer’s disease. For this reason, many people dream of an efficient method for losing weight. An international team of researchers led by Professor Alexander Pfeifer from the University Hospital Bonn, have now come one step closer to this goal. The scientists discovered a new way to stimulate brown fat and thus burn energy from food: The body’s own adenosine activates brown fat and “browns” white fat. The results are now being published in the renowned journal “Nature”.
“Not all fat is equal,” says Professor Alexander Pfeifer from the Institute of Pharmacology and Toxicology of the University Hospital Bonn. Humans have two different types of fat: undesirable white fat cells which form bothersome “love handles”, for example, as well as brown fat cells, which act like a desirable heater to convert excess energy into heat. “If we are able to activate brown fat cells or to convert white fat cells into brown ones, it might be possible to simply melt excess fat away” reports the pharmacologist.
The group of Prof. Pfeifer together with an international team from Sweden, Denmark, Finland, as well as from the Helmholtz-Center Dresden-Rossendorf and the University of Düsseldorf now discovered a new signalling molecule capable of activating brown fat cells: adenosine. Adenosine is typically released during stress. Crucial for transmitting the adenosine signal is the adenosine receptor A2A.
Adenosine activates brown adipose tissue
“If adenosine binds to this receptor in brown fat cells, fat burning is significantly stimulated,” reports Dr. Thorsten Gnad from Prof. Pfeifer’s team. It was previously thought not possible for adenosine to activate brown fat. Several studies with rats and hamsters demonstrated that adenosine blocks brown fat.
However, the researchers from the University of Bonn were not mislead by these previous findings. In contrast, using brown fat cells removed from humans during surgery, the scientists investigated the signaling pathway for fat activation using adenosine. The results showed that rats and hamsters react differently than humans in this regard. “The brown fat in mice on the other hand behaves just as in humans,” summarizes Prof. Pfeifer.
The Latest on: Adenosine
via Google News
The Latest on: Adenosine
- Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASHon June 23, 2020 at 11:21 pm
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic ...
- Adenosine and Adenosine Receptors in Rheumatoid Arthritison June 22, 2020 at 5:00 pm
Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.
- Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progressionon June 17, 2020 at 11:27 am
Editing of adenosine to inosine (A-to-I) in double-stranded RNA (dsRNA), catalyzed by adenosine deaminase acting on RNA (ADAR) family of enzymes, is the most common type of RNA editing in mammals (1).
- Adenosine in weight-loss therapy?on June 11, 2020 at 5:00 pm
Hailed as a health hack, intermittent fasting is widely promoted as a reliable way to lose weight, lower disease risk and increase lifespan. But despite some positive study results, does it really ...
- The adenosine pathway in immuno-oncologyon June 8, 2020 at 5:31 am
Over the past decade, remarkable progress has been made in the development of ‘next-generation’ therapeutics in immuno-oncology, with inhibitors of extracellular adenosine (eADO) signalling ...
- iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directorson May 31, 2020 at 10:00 pm
The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway ...
- Poxel announces new preclinical results from AMPK platform, PXL770 for NASH combinations & other metabolic diseaseon May 26, 2020 at 7:00 am
Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and NASH, announced new preclinical results for PXL770, the ...
- Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Officeon May 21, 2020 at 4:27 am
The allowed patent covers the use of the A3 adenosine receptor (A3AR) in reducing ectopic fat accumulation, particularly in fatty liver. The patent specifically addresses preparation of a ...
- Surface Oncology Shares Trade Up 40% on Phase 1 Study Plans for SRF617 Combined with Merck's KEYTRUDAon May 20, 2020 at 10:52 am
The company explained that "SRF617 inhibits CD39, an enzyme critical both to the breakdown of adenosine triphosphate and the production of adenosine and that a substantial body of research supports a ...
- Adenosine 6 mg/2 mL injectionon January 6, 2020 at 12:29 pm
This leaflet answers some common questions about Adenosine Mylan. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All ...
via Bing News